BOSTON– Orum Therapeutics announced it has secured approximately $100 million in new financing to accelerate the development of its degrader-antibody conjugate programs targeting cancer and other serious diseases.
The funding consists of 145 billion Korean won in convertible preferred stock investments and was led by returning investor KB Investment. Existing investors IMM Investment, Woori Venture Partners, and Stassets Investment also participated, along with new investors including Weiss Asset Management and Korea Investment Partners. Additional new participants in the round included DSC Investment, Company K Partners, AON Investment, and DAYLI Partners.
Orum said the financing will support the advancement of its lead program, ORM-1153, and other pipeline candidates toward clinical development. The company also plans to expand discovery efforts across new payload classes and continue refining its degrader-antibody conjugate platforms to generate next-generation therapeutic candidates.
“Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases,” said Sung Joo Lee, Ph.D., founder and chief executive officer of Orum Therapeutics. “This investment supports the next stage of our growth as we prepare to advance our next therapeutic programs towards clinical evaluation, develop additional novel payloads, and continue to build platforms that can generate differentiated drug candidates across oncology and beyond. We appreciate the confidence of both new and existing investors who share our commitment to delivering meaningful innovation for patients.”
Orum said the funding will also be used to broaden its scientific and operational capabilities as it advances additional targeted degrader-antibody conjugate programs designed around selectivity, potency, and rational payload design. The company believes these efforts will strengthen its position as a leader in next-generation DAC therapeutics for oncology and other serious diseases.
